CRSwNP market seen reaching $6.5B by 2030
The chronic rhinosinusitis with nasal polyps market is projected to climb from $4.78 billion in 2026 to $6.5 billion by 2030, according to The Business Research Company. Growth is being driven by rising respiratory disease cases, broader use of biologics and more demand for non-surgical treatment options.
Why it matters: - Chronic rhinosinusitis with nasal polyps, or CRSwNP, is gaining attention as respiratory disease rates rise and treatment options expand. - The market’s move toward biologics, imaging-led diagnosis and minimally invasive care could reshape how ENT conditions are managed. - The growth outlook signals more demand for drugs, diagnostics and outpatient procedures tied to long-term sinus inflammation.
What happened: - The Business Research Company released its Chronic Rhinosinusitis Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the CRSwNP market will rise from $4.38 billion in 2025 to $4.78 billion in 2026. - The report forecasts the market will reach $6.5 billion by 2030, implying an 8.0% CAGR over the forecast period. - North America held the largest share of the CRSwNP market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes a free sample and the full report.
The details: - The market’s recent growth has been supported by more chronic sinus disorder cases. - Expanded use of corticosteroid nasal sprays has also lifted demand. - More frequent consultations with ENT specialists have contributed to market expansion. - Better access to advanced diagnostic imaging has improved detection and treatment. - Heightened awareness of inflammatory sinus diseases has increased diagnosis and care seeking. - The report points to increasing approvals of monoclonal antibody therapies as a future driver. - More investment in biologics research for ENT conditions is expected to support growth. - Growth in outpatient sinus surgery is another forecast driver. - A stronger focus on preventing disease recurrence is expected to shape treatment choices. - Patient preference for non-surgical treatment options is likely to support demand. - Key trends include wider adoption of biologic therapies for CRSwNP. - Other trends include growth in minimally invasive surgical methods and more emphasis on long-term inflammation management. - The report also flags personalized treatment approaches and stronger use of diagnostic imaging with biomarker analysis. - CRSwNP is a long-lasting inflammatory disorder of the sinuses and nasal passages. - The condition is marked by nasal polyps, which are benign swollen tissue masses caused by ongoing inflammation. - Diagnosis can involve symptom review, clinical examination, imaging, allergy tests and sometimes biopsy.
Between the lines: - Rising asthma and COPD rates are feeding demand for CRSwNP care because the conditions often overlap with broader airway inflammation. - The report cites a December 2023 National Center for Biotechnology Information projection that global COPD cases could approach 600 million by 2050. - Asia-Pacific and other emerging markets are positioned for faster growth as healthcare infrastructure investment rises and disease awareness improves. - The report’s focus on biomarkers, imaging and personalized treatment suggests a market moving toward more targeted care rather than one-size-fits-all therapy.
What's next: - More CRSwNP patients are likely to be treated with biologics as approvals expand. - Outpatient surgery volumes may rise as providers seek less invasive options. - Market growth will likely track respiratory disease prevalence, especially in regions investing in diagnostics and ENT care. - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and trend graphics.
The bottom line: - CRSwNP is moving from a niche ENT category to a faster-growing treatment market, with biologics, diagnostics and minimally invasive procedures driving the next phase of expansion.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
European Environmental News
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.